论文信息 - Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I - 字舞流文

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Paul D. Smith | B. Cho | Matthew J. Martin | D. Cross | J. Urosevic | S. Bickerton | Nicolas Floc'h | Afshan Ahmed | Jonathan P. Orme | Sangbin Lim | Nicolas Floc’h | Jonathan Orme